• AstraZeneca outlined a push into weight management, centered on oral GLP-1 receptor agonist elecoglipron as a potential multi-blockbuster asset.
• Phase IIb VISTA in obesity or overweight without type 2 diabetes showed up to 10.5% weight loss at week 26, extending to 11.8% at week 36.
• VISTA reported placebo-corrected weight loss at week 36 of up to 11.5%, with GI side effects most common; no liver safety signals flagged.
• Phase IIb SOLSTICE in type 2 diabetes showed up to 1.9% HbA1c reduction at week 26; weight loss was significantly greater than placebo at doses ≥25 mg.
• Management signaled Phase III starts in H2 2026, spanning obesity, type 2 diabetes, HFpEF, and CKD outcomes programs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on June 09, 2026, and is solely responsible for the information contained therein.